KLRS

Kalaris Therapeutics, Inc.

Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001754068 Biotech & Drug Discovery

$1.80 −0.07 (−3.74%)

Oct 26 4:00 PM ET · prev $1.87

Market cap

$47.4M

Nano cap

Median target

🔒 Subscribers only

Next earnings

Nov 18

in 23 days · EPS est. −$0.52

1 year

−63.0%

from $4.86 · Oct 27

30 days

−36.7%

from $2.85

52-week range

$1.80–10.98

at the low

Avg volume 20D

85.6K

Oct 19 spike 271.5K

Short interest

🔒 Subscribers only

Insider net

+$6.2M

1 buyer · 1 seller · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read MIXED 4 reports · 90 days

Balance 0 bearish · 0 bullish · 4 neutral oldest → newest, height = score

Avg score

·High conf. 2/4 ·Next Earnings date, Nov 18, 2026

Strongest NEUTRAL Kalaris Therapeutics reported Q2 2026 EPS of -$0.48, a 7.1% beat vs consensus of -$0.49, but net loss…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

B Dec 18 1 insider buy $5.0M at $10.42
S Mar 20 1 insider sell $12.9K at $6.72
B May 20 1 insider buy $1.2M at $4.83
A Jun 15 TD Cowen initiates
E Jun 23 FDA: Kalaris Announces Upcoming Presentation of TH103 Phase 1a…
R Jul 17 Kalaris Therapeutics reported positive expanded Phase 1a SAD data fo…
E Jul 17 FDA: Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD R…
R Jul 17 Kalaris Therapeutics reported positive additional Phase 1a SAD data…

Signal stack

Where each data set points today.

InsidersBULLISH

1 insider bought $6.2M at an average $8.53. 1 insider sold $12.9K. Price is 79% below their cost.
InstitutionsBULLISH

Q2 2026: 10 added (0 new), 5 trimmed or exited.
EstimatesFLAT

Current-quarter EPS estimate −$0.517 → −$0.516 over 90 days. 4 up, 2 down in 30 days.
TrendDOWNTREND

42% below its 50-day average. New closing low $1.80 on Oct 26.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
ROYAL BANK OF CANADA	NEAR_EXIT	12	—
VANGUARD CAPITAL MANAGEMENT LLC	ADD	398,712	$1.6M
UBS Group AG	DOUBLED	262,131	$1.1M
RENAISSANCE TECHNOLOGIES LLC	DOUBLED	149,351	$607.9K
MARSHALL WACE, LLP	DOUBLED	139,201	$566.5K
GEODE CAPITAL MANAGEMENT, LLC	ADD	114,037	$464.3K
MORGAN STANLEY	ADD	72,326	$294.4K
VANGUARD FIDUCIARY TRUST CO	ADD	66,179	$269.3K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jun 2026

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access

Recent actions

Date	Firm	Action	Rating
Jun 15, 2026	TD Cowen INITIATE	INITIATE	Buy
May 14, 2026	Wedbush INITIATE	INITIATE	Outperform
May 13, 2026	Citizens MAINTAIN	MAINTAIN	Market Outperform

Insider ledger

Form 4

$6.2M

bought · 1 insider

$12.9K

sold · 1 insider

−78.9%

vs their $8.53 cost

Date	Insider	Type	Value
Aug 27, 2026	Vandekop Amy O'Leary VP, Corporate Controller	AWARD	10,000 sh
Aug 1, 2026	KEATING LAURIE Director	AWARD	18,000 sh
Jul 20, 2026	Bayko Liisa Ann Chief Financial Officer	AWARD	220,000 sh
Jun 3, 2026	PATTERSON LEONE D Director	AWARD	9,000 sh
Jun 3, 2026	ADAMIS ANTHONY P Director	AWARD	9,000 sh
Jun 3, 2026	Dybbs Michael Director	AWARD	9,000 sh
Jun 3, 2026	AKKARAJU SRINIVAS Director	AWARD	9,000 sh
Jun 3, 2026	Hallal David Director	AWARD	9,000 sh

Earnings setup

Estimates

Nov 18

reports in 23 days

−$0.52

EPS estimate, this quarter

+0%

estimate change, 90 days

4↑ 2↓

revisions, 30 days

Current-quarter EPS estimate

−$0.517

90d

−$0.521

60d

−$0.521

30d

−$0.516

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.52	-$0.57–-$0.40	+1.0%	$0.00
Next Q	-$0.54	-$0.59–-$0.48	+0.2%	$0.00
Current FY	-$2.00	-$2.08–-$1.85	+0.3%	$0.00
Next FY	-$1.65	-$2.20–$0.70	+0.4%	$11.4M